%0 Journal Article
%T Neoadjuvant PD-1 blockade in non-small cell lung cancer: what else do we need to do?
%A Bo Lu
%A Hecheng Li
%A Su Yang
%A Wei Guo
%A Wentian Zhang
%J SCIE-indexed Journal
%D 2018
%R 10.21037/jtd.2018.07.84
%X For decades, systemic therapy for non-small cell lung cancer (NSCLC) was subjected to cytotoxic agents. For patients with locally advanced NSCLC (stages IIIA¨CB) not suitable to surgical resection, the current standard of regimen is concurrent chemoradiotherapy, which induces median survival time in excess of 2- and 5-year survival of 15¨C20% (1). For advanced NSCLC patients, the application of third-generation of chemotherapy drugs such as docetaxel, paclitaxel and gemcitabine, had improved the overall survival to 8 months (2). For resectable NSCLC patients, neoadjuvant chemotherapy would significantly improve the overall survival (HR =0.84; 95% CI, 0.77¨C0.92; P=0.0001). With regard to stage III NSCLC, the result was similar (HR =0.84; 95% CI, 0.75¨C0.95; P=0.005) (3). However, in 2002, Carney concluded that we had reached a plateau of efficacy in NSCLC, which cannot be improved further with conventional chemotherapeutic drugs (4)
%U http://jtd.amegroups.com/article/view/22910/html